Urology practice · 2026
Advanced Practice Provider-Attributed Outpatient Visits and Procedures for Urologic Oncology Care in the United States.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Weitzner Aidan S, Kodavatikanti Achyutha, Alvim Laura, Lokeshwar Soum D, Cronin Craig, Korn Philipp, Singla Nirmish
Аннотация
INTRODUCTION: Integration of advanced practice providers (APPs) into the clinic setting holds potential to streamline care in urologic oncology. The impact of APP-attributed care in genitourinary oncology has not been well described. We sought to characterize national trends and the financial impact of APP-attributed outpatient visits and procedures within a privately insured urologic oncology population.
METHODS: We identified bladder, kidney, prostate, and testis cancer claims within the Merative MarketScan database from 2010 to 2023. Annual proportions of first-visit, overall, and select procedural APP-attributed claims were assessed descriptively. Comparisons by geographic status, urbanicity, insurance plan, and metastatic status were evaluated using chi-squared testing and multivariable modeling. Overall and out-of-pocket twelve-month health expenditures were assessed by whether first oncologic visit was APP-attributed.
RESULTS: There were 507,053 APP-attributed claims, increasing from 0.88% in 2010 to 3.38% in 2023. In adjusted analysis, later calendar year (OR: 1.1; p<0.001) had significantly higher odds of APP involvement, while residence within the Northeast (OR: 0.68; p<0.001) had significantly lower odds. APP-attributed first visits were associated with lower 12-month insurer-paid (SR: 0.81; p<0.001) and out-of-pocket (SR: 0.90; p<0.001) spending. Rates of APP-attributed cystoscopy and prostate biopsy remained modest.
CONCLUSION: APP-attributed office and procedural outpatient visits are increasing, with variations in uptake present by practice region and patient characteristics. APP-attributed first visits were associated with lower 12-month insurer-paid spending without increased patient out-of-pocket spending.
METHODS: We identified bladder, kidney, prostate, and testis cancer claims within the Merative MarketScan database from 2010 to 2023. Annual proportions of first-visit, overall, and select procedural APP-attributed claims were assessed descriptively. Comparisons by geographic status, urbanicity, insurance plan, and metastatic status were evaluated using chi-squared testing and multivariable modeling. Overall and out-of-pocket twelve-month health expenditures were assessed by whether first oncologic visit was APP-attributed.
RESULTS: There were 507,053 APP-attributed claims, increasing from 0.88% in 2010 to 3.38% in 2023. In adjusted analysis, later calendar year (OR: 1.1; p<0.001) had significantly higher odds of APP involvement, while residence within the Northeast (OR: 0.68; p<0.001) had significantly lower odds. APP-attributed first visits were associated with lower 12-month insurer-paid (SR: 0.81; p<0.001) and out-of-pocket (SR: 0.90; p<0.001) spending. Rates of APP-attributed cystoscopy and prostate biopsy remained modest.
CONCLUSION: APP-attributed office and procedural outpatient visits are increasing, with variations in uptake present by practice region and patient characteristics. APP-attributed first visits were associated with lower 12-month insurer-paid spending without increased patient out-of-pocket spending.